This company has been marked as potentially delisted and may not be actively trading. SpringWorks Therapeutics (SWTX) Stock Forecast & Price Target Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsEarningsFDA EventsHeadlinesInsider TradesOwnershipShort InterestTrendsBuy This Stock Get the Latest News and Ratings for SWTX and Related Stocks Enter your email address to receive the latest news and analysts' ratings for SpringWorks Therapeutics and its competitors. Enter your email to sign up for newsletter Sign Up SWTX Analyst Ratings Over TimeTypeCurrent Forecast8/11/24 to 8/11/251 Month Ago7/12/24 to 7/12/253 Months Ago5/13/24 to 5/13/251 Year Ago8/12/23 to 8/11/24Strong Buy0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)Buy1 Buy rating(s)1 Buy rating(s)1 Buy rating(s)6 Buy rating(s)Hold7 Hold rating(s)7 Hold rating(s)7 Hold rating(s)0 Hold rating(s)Sell0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)Consensus Price Target$52.57$52.57$52.57$68.83Forecasted Upside11.88% Upside11.88% Upside13.74% Upside84.00% UpsideConsensus RatingHoldHoldHoldBuy SWTX Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History SWTX Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table SpringWorks Therapeutics Stock vs. The CompetitionTypeSpringWorks TherapeuticsMedical CompaniesS&P 500Consensus Rating Score 2.13 2.81 2.53Consensus RatingHoldModerate BuyModerate BuyPredicted Upside11.88% Upside27,936.97% Upside13.84% UpsideNews Sentiment RatingNeutral NewsSee Recent SWTX NewsNeutral NewsPositive News Recent Analyst Forecasts and Stock Ratings All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Years 5 Years Time Frame Start Date End Date Most Recent from Each Brokerage All Show Export to Excel DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails5/12/2025Guggenheim2 of 5 starsM. SchmidtSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$47.00 ➝ $47.00+1.81%4/30/2025HC Wainwright1 of 5 starsRobert BurnsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$74.00 ➝ $47.00+1.64%4/29/2025Cowen1 of 5 stars DowngradeHold4/29/2025TD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingYaron WerberSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$66.00 ➝ $47.00+1.78%4/28/2025Evercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingC. KasimovSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/28/2025BarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingPeter LawsonSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$63.00 ➝ $47.00+1.79%4/28/2025WedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingD. NierengartenSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Neutral$81.00 ➝ $47.00+1.94%9/4/2024JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy rating Boost TargetOverweight ➝ Overweight$64.00 ➝ $68.00+65.93%11/29/2023The Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy rating Boost TargetBuy ➝ Buy$47.00 ➝ $52.00+93.16%Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 04:23 AM ET. SWTX Forecast - Frequently Asked Questions What is SpringWorks Therapeutics' forecast for 2025? According to the research reports of 8 Wall Street equities research analysts, the average twelve-month stock price forecast for SpringWorks Therapeutics is $52.57, with a high forecast of $68.00 and a low forecast of $47.00. Should I buy or sell SpringWorks Therapeutics stock right now? 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for SpringWorks Therapeutics in the last year. There are currently 7 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" SWTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SWTX, but not buy additional shares or sell existing shares. Does SpringWorks Therapeutics's stock price have much upside? According to analysts, SpringWorks Therapeutics's stock has a predicted upside of 11.88% based on their 12-month stock forecasts. Do Wall Street analysts like SpringWorks Therapeutics more than its competitors? Analysts like SpringWorks Therapeutics less than other "medical" companies. The consensus rating for SpringWorks Therapeutics is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how SWTX compares to other companies. Stock Forecasts and Research Tools Related Companies Genmab A/S Stock Forecast Dr. Reddy's Laboratories Stock Forecast Qiagen Stock Forecast Moderna Stock Forecast Ascendis Pharma A/S Stock Forecast Viatris Stock Forecast BridgeBio Pharma Stock Forecast Verona Pharma PLC American Depositary Share Stock Forecast Blueprint Medicines Stock Forecast Roivant Sciences Stock Forecast Today's Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter This page (NASDAQ:SWTX) was last updated on 8/11/2025 by MarketBeat.com Staff From Our PartnersYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SpringWorks Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share SpringWorks Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access Sale